OSE Pharma SA
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II c… Read more
OSE Pharma SA (OSE) - Net Assets
Latest net assets as of June 2025: €50.60 Million EUR
Based on the latest financial reports, OSE Pharma SA (OSE) has net assets worth €50.60 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€104.18 Million) and total liabilities (€53.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €50.60 Million |
| % of Total Assets | 48.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | 4.2% |
| 10-Year Change | 340.81% |
| Growth Volatility | 121.41 |
OSE Pharma SA - Net Assets Trend (2012–2024)
This chart illustrates how OSE Pharma SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OSE Pharma SA (2012–2024)
The table below shows the annual net assets of OSE Pharma SA from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €63.81 Million | +177.74% |
| 2023-12-31 | €22.98 Million | -29.41% |
| 2022-12-31 | €32.55 Million | -31.53% |
| 2021-12-31 | €47.53 Million | -22.38% |
| 2020-12-31 | €61.24 Million | +4.69% |
| 2019-12-31 | €58.49 Million | -5.28% |
| 2018-12-31 | €61.75 Million | +11.38% |
| 2017-12-31 | €55.45 Million | -14.07% |
| 2016-12-31 | €64.53 Million | +345.74% |
| 2015-12-31 | €14.48 Million | +1902.74% |
| 2014-12-31 | €-803.00K | +7.06% |
| 2013-12-31 | €-864.00K | -36.49% |
| 2012-12-31 | €-633.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to OSE Pharma SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1643500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €4.39 Million | 6.88% |
| Other Comprehensive Income | €-293.00K | -0.46% |
| Other Components | €77.59 Million | 121.59% |
| Total Equity | €63.81 Million | 100.00% |
OSE Pharma SA Competitors by Market Cap
The table below lists competitors of OSE Pharma SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Panca Anugrah Wisesa Tbk PT
JK:MGLV
|
$58.44 Million |
|
Territorial Bancorp Inc
NASDAQ:TBNK
|
$58.46 Million |
|
Tunghsu Azure Renewable Energy Co Ltd
SHE:000040
|
$58.47 Million |
|
Zen Voce
TWO:3581
|
$58.49 Million |
|
Agrify Corp
NASDAQ:AGFY
|
$58.43 Million |
|
EMEK Elektrik Endustrisi AS
IS:EMKEL
|
$58.43 Million |
|
Cantabil Retail India Limited
NSE:CANTABIL
|
$58.42 Million |
|
Kangnam Jevisco Co Ltd
KO:000860
|
$58.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OSE Pharma SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 22,821,000 to 63,811,000, a change of 40,990,000 (179.6%).
- Net income of 37,445,000 contributed positively to equity growth.
- Share repurchases of 1,157,000 reduced equity.
- New share issuances of 1,157,000 increased equity.
- Other comprehensive income increased equity by 16,000.
- Other factors increased equity by 3,529,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €37.45 Million | +58.68% |
| Share Repurchases | €1.16 Million | -1.81% |
| Share Issuances | €1.16 Million | +1.81% |
| Other Comprehensive Income | €16.00K | +0.03% |
| Other Changes | €3.53 Million | +5.53% |
| Total Change | €- | 179.62% |
Book Value vs Market Value Analysis
This analysis compares OSE Pharma SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | €-0.08 | €3.58 | x |
| 2013-12-31 | €-0.11 | €3.58 | x |
| 2014-12-31 | €-0.10 | €3.58 | x |
| 2015-12-31 | €1.52 | €3.58 | x |
| 2016-12-31 | €4.75 | €3.58 | x |
| 2017-12-31 | €3.86 | €3.58 | x |
| 2018-12-31 | €3.98 | €3.58 | x |
| 2019-12-31 | €3.93 | €3.58 | x |
| 2020-12-31 | €3.94 | €3.58 | x |
| 2021-12-31 | €2.64 | €3.58 | x |
| 2022-12-31 | €1.76 | €3.58 | x |
| 2023-12-31 | €1.17 | €3.58 | x |
| 2024-12-31 | €2.93 | €3.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OSE Pharma SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 58.68%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 53.59%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.94x
- Recent ROE (58.68%) is above the historical average (-14.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.37 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | €-163.60K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | €-2.75 Million |
| 2015 | -38.57% | -139600.00% | 0.00x | 1.17x | €-7.03 Million |
| 2016 | 32.03% | 5395.82% | 0.00x | 1.39x | €14.21 Million |
| 2017 | -18.94% | -157.18% | 0.09x | 1.40x | €-16.05 Million |
| 2018 | 8.89% | 22.45% | 0.32x | 1.25x | €-685.40K |
| 2019 | -7.95% | -17.93% | 0.29x | 1.52x | €-10.50 Million |
| 2020 | -27.03% | -158.91% | 0.11x | 1.58x | €-22.68 Million |
| 2021 | -35.18% | -64.05% | 0.26x | 2.12x | €-21.64 Million |
| 2022 | -54.57% | -97.04% | 0.20x | 2.82x | €-21.01 Million |
| 2023 | -100.80% | -1032.91% | 0.03x | 3.60x | €-25.29 Million |
| 2024 | 58.68% | 53.59% | 0.56x | 1.94x | €31.06 Million |
Industry Comparison
This section compares OSE Pharma SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,397,324
- Average return on equity (ROE) among peers: -51.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OSE Pharma SA (OSE) | €50.60 Million | 0.00% | 1.06x | $58.44 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |